Eisai to Present Clinical Trial and Biomarker Exploration Results of E7386, Co-Created with PRISM BioLab, at the ESMO Annual Congress

Published on: October 21, 2025

TOKYO, Japan, October 17, 2025: — PRISM BioLab announces that Eisai Co., Ltd. will present clinical trial results and biomarker exploration data for E7386, co-created by PRISM BioLab and Eisai, in combination with lenvatinib mesylate, at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 22, 2025. The abstract of the study has been disclosed today.

Read Full Press Release